2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 504

Raynaud’s Phenomenon and African American Race Are Independently Associated With Non-Hodgkin’s Lymphoma In Sjogrens Syndrome Patients: Findings From a United States National Study
Abstract Number: 1791

Reaching The Target Of Low Disease Activity At 6 Months Predicts Better Long-Term Functional Outcome In Patients With Early Rheumatoid Arthritis
Abstract Number: 1030

Readability of Participant Information and Consent Forms for Rheumatology Clinical Trial Participants
Abstract Number: 1718

Reading Of The Sacroiliac Joints On Plain Radiographs: Agreement Between Clinical Practice and Trained Central Reading Of The DESIR-Cohort
Abstract Number: 2852

Real-Life Assessment Of The Validity Of Patient Global Impression Of Change In Fibromyalgia
Abstract Number: 473

Real-World Effectiveness and Safety Of Infliximab In The Treatment Of Rheumatoid Arthritis Over 5 Years: The Canadian Experience
Abstract Number: 1554

Real-World Effectiveness Of Infliximab In The Treatment Of Psoriatic Arthritis Over 12 Months: The Canadian Experience
Abstract Number: 1468

Reasons For Discontinuation Of Biologic Agents In Rheumatoid Arthritis Patients
Abstract Number: 849

Reasons For Failure To Obtain Influenza and Pneumococcal Vaccines Among Immunosuppressed Individuals With Systemic Lupus Erythematosus
Abstract Number: 794

Recent Trends In Medication Usage for the Treatment of Juvenile Idiopathic Arthritis and the Influence of TNF Inhibitors
Abstract Number: 2647

Recombinant Monoclonal Antibodies Derived From Single CD19+ Synovial B Cells Of RA Patients With Tertiary Lymphoid Structures Display a Strong Immunoreactivity Towards Citrullinated Histones
Abstract Number: 2579

Recommendations For Screening and Detection Of Connective-Tissue Disease Associated Pulmonary Arterial Hypertension
Abstract Number: 838

Recommendations for the Classification and Diagnosis of Fibromyalgia Syndrome Provided By Independently Developed Evidence-Based Interdisciplinary Guidelines Spanning Three Continents
Abstract Number: 2127

Recurrences Of Hallux Valgus Deformity After Implant Surgery For Greater Toe In Rheumatoid Arthritis
Abstract Number: 2751

Recurrent Pericarditis In Children and Adolescents: Etiology, Presentation, Therapies, and Outcomes In a Multicenter Retrospective Cohort Of 100 Patients

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].